gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 02 Oct 2014.

Cyclin-dependent kinase 9

TAK, CDK9, Cyclin-Dependent Kinase 9
The protein encoded by this gene is a member of the cyclin-dependent protein kinase (CDK) family. CDK family members are highly similar to the gene products of S. cerevisiae cdc28, and S. pombe cdc2, and known as important cell cycle regulators. This kinase was found to be a component of the multiprotein complex TAK/P-TEFb, which is an elongation factor for RNA polymerase II-directed transcription and functions by phosphorylating the C-terminal domain of the largest subunit of RNA polymerase II. This protein forms a complex with and is regulated by its regulatory subunit cyclin T or cyclin K. HIV-1 Tat protein was found to interact with this protein and cyclin T, which suggested a possible involvement of this protein in AIDS. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: PCNA, POLYMERASE, CAN, V1a, ACID
Papers using TAK antibodies
Identification of the vesicular nucleotide transporter (VNUT) in taste cells.
Meyerhof Wolfgang, In PLoS ONE, 2008
... Slices containing vallate taste buds were mounted on a glass coverslip coated with Cell-Tak (Becton Dickinson, Franklin Lakes, NJ, USA), ...
In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector
Fujinaga Koh et al., In Retrovirology, 1995
... Anti-myc, anti-HA, anti-CycT1, anti-Cdk9, and anti-Ub antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) ...
Papers on TAK
Relaxin augments BMP-2-induced osteoblast differentiation and bone formation.
Ko et al., Kwangju, South Korea. In J Bone Miner Res, Jul 2014
Interestingly, Rln synergistically increased and sustained BMP-2-induced Smad, p38, and transforming growth factor-β activated kinase (TAK) 1 phosphorylation.
Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome.
AXIOM investigators et al., Detroit, United States. In Thromb Haemost, Jun 2014
TAK-442 is an oral direct factor Xa inhibitor.
Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors.
Mestres et al., Barcelona, Spain. In Oncotarget, Jun 2014
In this respect, rucaparib inhibits nine kinases with micromolar affinity, including PIM1, PIM2, PRKD2, DYRK1A, CDK1, CDK9, HIPK2, CK2, and ALK.
Evolution of genetic polymorphisms of Plasmodium falciparum merozoite surface protein (PfMSP) in Thailand.
Na-Bangchang et al., Thailand. In Korean J Parasitol, Feb 2014
The genetic diversity of the merozoite surface protein-1 (PfMSP-1) and merozoite surface protein-2 (PfMSP-2) genes was investigated in a total of 145 P. falciparum isolates collected from Mae Sot District, Tak Province, Thailand during 3 different periods (1997-1999, 2005-2007, and 2009-2010).
Beyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer.
Pinto, Madrid, Spain. In Cancer Biol Ther, Feb 2014
New androgen biosynthesis inhibitors have been developed, such as orteronel (TAK-700), but also new antiandrogens (enzalutamide, ARN-509, ODM-201) or even agents with a dual mechanism of action (galeterone).
Nonproteolytic roles of 19S ATPases in transcription of CIITApIV genes.
Greer et al., Atlanta, United States. In Plos One, Dec 2013
Additionally, these ATPases interact with elongation factor PTEFb complex members CDK9 and Hexim-1 and with Ser5 phosphorylated RNA Pol II.
Activation of GPR40 as a therapeutic target for the treatment of type 2 diabetes.
Burant, Ann Arbor, United States. In Diabetes Care, Aug 2013
Recent phase I and phase II clinical trials in humans have shown that the GPR40 agonist TAK-875 reduces fasting and postprandial blood glucose and lowers HbA1c with efficacy equal to that of the sulfonylurea glimepiride without inducing hypoglycemia or evidence of tachyphylaxis.
HIF1A employs CDK8-mediator to stimulate RNAPII elongation in response to hypoxia.
Espinosa et al., Boulder, United States. In Cell, Jul 2013
HIF1A induces binding of CDK8-Mediator and the super elongation complex (SEC), containing AFF4 and CDK9, to alleviate RNAPII pausing.
Cyclin-dependent kinase inhibitor therapy for hematologic malignancies.
Grant et al., Richmond, United States. In Expert Opin Investig Drugs, Jun 2013
Certain CDKs (e.g., CDK7, CDK9) also control cellular transcription.
Lost in transcription: molecular mechanisms that control HIV latency.
Peterlin et al., Beersheba, Israel. In Viruses, Mar 2013
Among these, transcriptional repression as a result of reduced levels and activity of the positive transcription elongation factor b (P-TEFb: CDK9/cyclin T) plays a significant role.
Efficacy and toxicity of factor Xa inhibitors.
Vanelle et al., Marseille, France. In J Pharm Pharm Sci, 2012
New antithrombotics such as rivaroxaban, apixaban, betrixaban, edoxaban, darexaban, TAK-442, LY517717, eribaxaban, otamixaban are being developed to overcome current therapeutic limitations.
The super elongation complex (SEC) family in transcriptional control.
Shilatifard et al., Kansas City, United States. In Nat Rev Mol Cell Biol, 2012
Studies indicate that the super elongation complex (SEC) consisting of ELL, P-TEFb (CDK9) and MLL required for rapid transcriptional induction in the presence or absence of paused RNA polymerase II (Pol II).
Separate domains of fission yeast Cdk9 (P-TEFb) are required for capping enzyme recruitment and primed (Ser7-phosphorylated) Rpb1 carboxyl-terminal domain substrate recognition.
Fisher et al., New York City, United States. In Mol Cell Biol, 2012
a Cdk9 carboxyl-terminal extension, distinct from the catalytic domain, mediates binding to both Pcm1 and the Pol II carboxyl-terminal domain
Phosphorylation by cyclin-dependent kinase-9 controls ubiquitin-conjugating enzyme-2A function.
Johnsen et al., Göttingen, Germany. In Cell Cycle, 2012
CDK9 phosphorylates UBE2A and regulates UBE2A-mediated monoubiquitination of both H2B and PCNA.
TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial.
Leifke et al., Ann Arbor, United States. In Lancet, 2012
We aimed to assess whether selective pharmacological activation of this receptor by TAK-875 in patients with type 2 diabetes mellitus improved glycaemic control without hypoglycaemia risk.
Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor α and bcr-abl oncogene addiction in malignant hematologic cells.
Pan et al., Guangzhou, China. In Clin Cancer Res, 2012
Data show that the cyclin-dependent kinase 7/9 inhibitor (CDK7/9 inhibitor) potently inhibits FIP1L1-PDGFRalpha-positive Bcr-Abl-positive chronic myeloid leukemia (CML) cells.
Flavopiridol induces phosphorylation of AKT in a human glioblastoma cell line, in contrast to siRNA-mediated silencing of Cdk9: Implications for drug design and development.
Giordano et al., Philadelphia, United States. In Cell Cycle, 2012
siRNA-mediated inhibition of Cdk9 caused a shift from G 0/G 1 to G 2/M phase in human PC3 prostate cancer cell line.
RNAP II CTD phosphorylated on threonine-4 is required for histone mRNA 3' end processing.
Manley et al., New York City, United States. In Science, 2011
Like Ser(2), Thr(4) phosphorylation requires the CTD kinase CDK9 and is evolutionarily conserved from yeast to human.
Crystal structure of HIV-1 Tat complexed with human P-TEFb.
Price et al., Omaha, United States. In Nature, 2010
Here we describe the crystal structure of the Tat.P-TEFb complex containing HIV-1 Tat, human Cdk9 (also known as CDK9), and human cyclin T1 (also known as CCNT1).
Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-beta pathways.
Massagué et al., New York City, United States. In Cell, 2009
As receptor-activated Smads form transcriptional complexes, they are phosphorylated at an interdomain linker region by CDK8 and CDK9, which are components of transcriptional mediator and elongation complexes.
share on facebooktweetadd +1mail to friends